Brand Name :
Briumvi, ublituximab-xiiy
Synonyms :
ublituximab
Class :
Neurologic, monoclonal antibody
Dosage Forms & Strengths
Injectable solution
25mg/ml
First infusion:150 mg intravenous
Second infusion: After two weeks of the first infusion, administer 450mg intravenous
Further infusions: After 24 weeks of the first infusion, administer 450mg intravenous
Dosage Forms & Strengths
Safety and efficacy not established
Refer adult dosing
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
may have an increased immunosuppressive effect when combined with ublituximab
It may enhance the immunosuppressive effects when combined with risankizumab
atoltivimab/maftivimab/odesivimab
atoltivimab/maftivimab/odesivimab and ublituximab together reduce immunosuppressive effects
It may enhance the effects when combined with triamcinolone by immunosuppressive effects
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
ublituximab: they may increase the immunosuppressive effect of immunostimulants
may decrease the therapeutic effect of immunosuppressants
may increase the immunosuppressive effect of immunosuppressants
may increase the immunosuppressive effect of Immunosuppressive agents
It may enhance the adverse effects when combined with sotrovimab
may increase the immunosuppressive effect of Immunosuppressants
Frequency defined:
>10%
Upper respiratory tract infections
Reactions at the infusion site
1-10%
Infections associated with the herpes virus
Extremity pain
Fatigue
Lower respiratory tract infections
Insomnia
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: ublituximab
Pronounced: (ue” bli tux’ i mab)
Why do we use ublituximab?
Ublituximab (also known as Tuxella) is a monoclonal antibody being investigated for its potential use in treating multiple sclerosis (MS). It is designed to target a specific protein called CD20 found on certain immune cells’ surfaces called B cells. In people with MS, B cells are thought to play a role in the immune system’s attack on the protective coating (called myelin) surrounding nerve fibers in the brain and spinal cord.
By targeting CD20, ublituximab may help to reduce the number of B cells in the body and potentially reduce inflammation and nerve damage in people with MS. However, ublituximab is still being investigated in clinical trials, and regulatory agencies have not yet approved it for use in the treatment of MS or any other condition.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
